S140: SINGLE-CELL MULTIOMICS ANALYSES REVEAL COMPLEX INTRA-PATIENT HETEROGENEITY IN RELAPSED CLL FOLLOWING VENETOCLAX THERAPY

S140: SINGLE-CELL MULTIOMICS ANALYSES REVEAL COMPLEX INTRA-PATIENT HETEROGENEITY IN RELAPSED CLL FOLLOWING VENETOCLAX THERAPY

Bibliographic Details
Main Authors:	R. Thijssen, L. Tian, C. Flensburg, M. A. Anderson, A. Jarratt, H. Peng, I. Majewski, C. Tam, J. Seymour, P. Blombery, M. Ritchie, D. Huang, A. Roberts
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000843452.53281.c8

Similar Items

Update on the role of venetoclax and rituximab in the treatment of relapsed or refractory CLL
by: James D’Rozario, et al.
Published: (2019-05-01)

S140: IBRUTINIB SENSITIZES CLL CELLS TO VENETOCLAX BY INTERRUPTING TLR9-INDUCED CD40 UPREGULATION AND PROTEIN TRANSLATION
by: Karoline Kielbassa, et al.
Published: (2023-08-01)

Review of Venetoclax in CLL, AML and Multiple Myeloma
by: Masa Lasica, et al.
Published: (2021-05-01)

PB1863: BRUIN CLL-322: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB+VENETOCLAX AND RITUXIMAB VS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CLL/SLL (TRIAL IN PROGRESS)
by: A. R. Mato, et al.
Published: (2022-06-01)

Venetoclax: A Novel Therapeutic Agent for CLL with CNS Involvement
by: Nishika Karbhari, et al.
Published: (2022-03-01)

Progressive Multifocal Leukoencephalopathy in B-CLL Successfully Treated With Venetoclax and Pembrolizumab
by: Jacopo Olivieri, et al.
Published: (2022-06-01)

Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication
by: Pin Lu, et al.
Published: (2021-02-01)

P641: RETREATMENT WITH VENETOCLAX AFTER VENETOCLAX, OBINUTUZUMAB +/- IBRUTINIB: POOLED ANALYSIS OF 13 PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) TREATED IN GCLLSG TRIALS
by: P. Cramer, et al.
Published: (2022-06-01)

JAK–STAT signalling shapes the NF‐κB response in CLL towards venetoclax sensitivity or resistance via Bcl‐XL
by: Marco V. Haselager, et al.
Published: (2023-06-01)

Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations
by: Richard W. Birkinshaw, et al.
Published: (2019-06-01)

CONCOMITANT USE OF VENETOCLAX 100 MG AND KETOCONAZOLE TO TREAT CLL IN A PUBLIC CENTER IN BRAZIL
by: FM Marques, et al.
Published: (2023-10-01)

MATCHING-ADJUSTED INDIRECT COMPARISON OF PIRTOBRUTINIB VS VENETOCLAX CONTINUOUS MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY CLL PREVIOUSLY TREATED WITH A COVALENT BTK INHIBITOR
by: O Al-Sawaf, et al.
Published: (2023-10-01)

P670: ABSENCE OF BTK, BCL2, AND PLCG2 MUTATIONS IN RELAPSING CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AFTER FIRST-LINE TREATMENT WITH FIXED-DURATION IBRUTINIB (I) PLUS VENETOCLAX (V)
by: L. J. Croner, et al.
Published: (2022-06-01)

Mutations driving CLL and their evolution in progression and relapse
by: Lander, Eric Steven
Published: (2017)

S201: FINAL 7-YEAR FOLLOW UP AND RETREATMENT SUBSTUDY ANALYSIS OF MURANO: VENETOCLAX-RITUXIMAB (VENR)-TREATED PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL)
by: Arnon Kater, et al.
Published: (2023-08-01)

S148: VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 5-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY
by: O. Al-Sawaf, et al.
Published: (2022-06-01)

P640: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN COMBINATION WITH VENETOCLAX±RITUXIMAB IN RELAPSED/REFRACTORY CLL: RESULTS FROM THE BRUIN PHASE 1B STUDY
by: L. E. Roeker, et al.
Published: (2022-06-01)

PB2353: HEALTHCARE RESOURCE UTILIZATION AND COSTS OFF THERAPY WITH FIXED-DURATION VENETOCLAX AMONG CLL PATIENTS
by: J. N. Allan, et al.
Published: (2022-06-01)

Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy
by: Sasanka Handunnetti, et al.
Published: (2021-05-01)

Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia
by: Paul J. Hampel, et al.
Published: (2021-03-01)

Case Report: Rapid renal response to venetoclax monotherapy in a CLL patient with secondary membranous glomerulonephritis
by: Ester Lovato, et al.
Published: (2023-04-01)

P623: MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF PIRTOBRUTINIB VS VENETOCLAX CONTINUOUS MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY CLL PREVIOUSLY TREATED WITH A COVALENT BTK INHIBITOR
by: Othman Al-Sawaf, et al.
Published: (2023-08-01)

RELAPSED UBTF-TD MDS TREATED WITH VENETOCLAX AND AZACITIDINE
by: Henrik Hasle, et al.
Published: (2023-12-01)

Azacytidine and Venetoclax in Relapsed and Refractory Patients With Angioimmunoblastic T-cell Lymphoma
by: Kamel Laribi, et al.
Published: (2022-02-01)

S145: VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 6-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY
by: Othman Al-Sawaf, et al.
Published: (2023-08-01)

RİCHTER SYNDROME TRANSFORMATİON UNDER VENETOCLAX TREATMENT: A CASE REPORT OF A 51-YEAR-OLD FEMALE WİTH CLL
by: İbrahim Halil Açar, et al.
Published: (2023-10-01)

P664: GRADING QUALITY OF EVIDENCE AND STRENGTH OF RECOMMENDATIONS FOR THE TREATMENT OF RELAPSED/REFRACTORY CLL.
by: S. Molica, et al.
Published: (2022-06-01)

P534: AZACITIDINE PLUS VENETOCLAX FOR THE TREATMENT OF RELAPSED AND FIRST-LINE AML PATIENTS
by: S. Garciaz, et al.
Published: (2022-06-01)

S148: TIME-LIMITED VENETOCLAX AND IBRUTINIB FOR PATIENTS WITH RELAPSED/REFRACTORY CLL WHO HAVE UNDETECTABLE MRD – 4-YEAR FOLLOW UP FROM THE RANDOMIZED PHASE II VISION/HO141 TRIAL
by: Arnon Kater, et al.
Published: (2023-08-01)

S144: IMMUNE RESTORATION AND SYNERGISTIC ACTIVITY WITH FIRST-LINE (1L) IBRUTINIB (IBR) PLUS VENETOCLAX (VEN): TRANSLATIONAL ANALYSES OF CAPTIVATE PATIENTS WITH CLL
by: I. Solman, et al.
Published: (2022-06-01)

Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL.
by: Guièze, R, et al.
Published: (2015)

Clinical Study of Venetoclax with Chemotherapy for Relapsed/Refractory Acute Myeloid Leukemia
by: CHEN Xiaofeng, WANG Meng, LI Zhongyu, LI Jiajia
Published: (2022-03-01)

Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Are Supporting Evidences Enough?
by: Serena Brancati, et al.
Published: (2021-12-01)

Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14)
by: Nina Nguyen, et al.
Published: (2022-10-01)

Ibrutinib protects T cells in patients with CLL from proliferation-induced senescence
by: Joanne E. Davis, et al.
Published: (2021-11-01)

PB1878: CROSS-TRIAL ANALYSIS OF FIXED-DURATION IBRUTINIB (I) PLUS VENETOCLAX (V) VS FLUDARABINE (F), CYCLOPHOSPHAMIDE (C), AND RITUXIMAB (R) AS FIRST-LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
by: J. C. Barrientos, et al.
Published: (2022-06-01)

PB1938: REAL WORLD EFFECTIVENESS AND SAFETY OF VENETOCLAX IN COMBINATION WITH OBINUTUZUMAB IN TREATMENT NAIVE CLL PATIENTS – DATA FROM THE OBSERVATIONAL STUDY VERVE
by: Ingo Schwaner, et al.
Published: (2023-08-01)

P647: SAFETY AND EFFECTIVENESS OF VENETOCLAX MONOTHERAPY IN R/R CLL PATIENTS WITH OR WITHOUT RISK-ASSOCIATED GENETIC MARKERS – DATA FROM THE OBSERVATIONAL VERVE STUDY
by: I. Schwaner, et al.
Published: (2022-06-01)

P622: GENETIC MARKERS AND OUTCOME OF CLL PATIENTS IN COMBINED TIME-LIMITED TREATMENT WITH ANTI-CD20 ANTIBODY + IBRUTINIB, IDELALISIB OR VENETOCLAX IN THE GCLLSG CLL2-BAG, -BCG, -BIG AND -BIO PHASE-II TRIALS
by: Deyan Yosifov, et al.
Published: (2023-08-01)

Combination of Venetoclax and Midostaurin Efficiently Suppressed Relapsed t(8;21)Acute Myeloid Leukemia With Mutant KIT After Failure of Venetoclax Plus Azacitidine Treatment
by: Zheng Li, et al.
Published: (2022-02-01)